Golden, Colorado—December 29, 2015 —Vitro Diagnostics, Inc. (OTCQB: VODG), dba Vitro Biopharma, announced new developments of its stem cell activation therapy for concussion. Dr. Omula’s research tying repetitive concussion to chronic traumatic encephalopathy is chronicled in the recently released movie, “Concussion.” Vitro Biopharma is a leader in the field of stem cell activation therapy now focused on treatment of concussion/TBI. This novel therapy results in activation of stem cells that reside within the brain to regenerate brain cells and restore function. The Company continues to develop this new technology into solutions for the devastating consequences of severe concussion. Our patent-pending technology provides various means for activation of stem cells residing within the brain to proliferate and migrate to sites of injury, including areas damaged by concussion. At the site of injury, stem cells differentiate into neurons, neural supporting cells called glial cells, such as astrocytes & oligodendrocytes, or cells of the vasculature to restore blood flow. Also, stem cells mediate various other regenerative effects including neuroprotection, reduction of inflammation, cell death and oxidative stress, through the secretion of biologically active substances at the site of injury. Vitro Biopharma’s technology includes methods of stem cell activation through small, biologically active molecules or external energy fields together with diagnostic measures that quantify cellular regeneration and other regenerative processes. While regeneration of nerve cells was once considered impossible, there are well-known regions within the brain where regeneration of nerve cells occurs including the olfactory epithelium and hippocampal regions underlying memory functions. Vitro Biopharma’s new technology targets activation of stem cells within these existing systems and provides mechanisms to expand neural regeneration to other regions of the brain as well.
The loss of cognitive and motor functions from concussion/TBI and neurodegenerative conditions such as Alzheimer’s, amyotrophic sclerosis (ALS) & Parkinson’s disease is currently considered to be a direct result of death of specific cells within the brain. For example, selective death of dopaminergic neurons of the substantia nigra (a brain region controlling motor function) leads to Parkinson’s disease. The stem cell system of the body is a natural method of cellular regeneration that mediates healing as well as normal development. Hence, the use of stem cell therapy holds significant potential for the treatment of TBI and neurodegenerative conditions as well. The activation of stem cells within the brain has the following advantages over stem cell transplants: 1) Removes the blood-brain barrier and other obstacles to the migration of stem cells into injured or degenerated brain regions requiring cellular regeneration to restore function, 2) No cellular transplants are needed, reducing potential for contamination and the overall costs of the procedure, 3) Reduced costs and time to obtain regulatory approval by FDA and other regulatory agencies.
Dr. Jim Musick, Vitro Biopharma’s president and CEO said, “In addition to advances in treatment procedures and diagnostics, Vitro Biopharma is developing a novel business plan to commercialize its brain regeneration technology. We are in discussions with key strategic business and financial partners to implement our business model involving concussion support services together with various research activities to validate the clinical effectiveness of our treatments. Through our leading position in adult stem cell growth & differentiation technology and products, we are developing collaboration with leading neurological research institutions to support our clinical studies. We have gained IND exempt status from the FDA that allows us to pursue clinical studies to test a novel combination of previously approved drugs for safety and efficacy in TBI patients. Stem cell activation therapy is strongly supported by a variety of pre-clinical studies, clinical studies and stem cell-based assay research conducted by Vitro Biopharma. A primary goal is to generate quantitative results in clinical studies to validate stem activation therapy and to direct further refinements of the therapy as well. In addition to TBI, we plan to pursue use of stem cell activation for treatment of other neurological conditions including autism, stroke and Alzheimer’s disease”
About Vitro Biopharma
Vitro Biopharma’s (http://www.vitrobiopharma.com/) mission is “Harnessing the Power of Cells™” for the advancement of regenerative medicine to its full potential. Vitro Biopharma operates within a modern, GMP-compliant biotechnology manufacturing and R&D facility in Golden, Colorado. Vitro Biopharma manufactures and sells “Tools for Stem Cell and Drug Development™”, including human mesenchymal stem cells and derivatives, the MSC-Gro™ Brand of optimized media for MSC self-renewal and lineage-specific differentiation. Our cell lines also include cancer-associated fibroblasts (CAFs) derived from lung, colorectal, ovarian, uterine and pancreatic tumors. In addition, we provide MSC-derived progenitor cells, including neural stem cells (NSCs), nephron progenitor cells (NPCs) as well as a growing line of terminally differentiated cells: cholinergic, dopaminergic and sensory neurons, osteoblasts, chondrocytes, cardiomyocytes, and renal tubular epithelial cells. A primary application of these terminally differentiated cells is cell-based assays for drug discovery and pre-clinical toxicology of drugs, drug candidates and drug combinations that may produce toxic effects on cardiac, neural or renal cells, either directly or through metabolites derived from the interaction of drugs with specific cells such as liver cells. Vitro Biopharma now provides its clinical grade MSC-Gro™ media for expansion of stem cells prior to transplantation for clinical studies of osteoarthritis treatment and products for use in preliminary studies of stem cell activation therapy for ASD & autoimmunity.
Vitro Biopharma received the Frost and Sullivan Technology Innovation Leadership Award for the industry sector: Stem Cell Tools and Technology in North America, 2014.
Safe Harbor Statement
Certain statements contained herein and subsequent statements made by and on behalf of the Company, whether oral or written may contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward looking statements are identified by words such as “intends,” “anticipates,” “believes,” “expects” and “hopes” and include, without limitation, statements regarding the Company’s plan of business operations, product research and development activities, potential contractual arrangements, receipt of working capital, anticipated revenues and related expenditures. Factors that could cause actual results to differ materially include, among others, acceptability of the Company’s products in the market place, general economic conditions, receipt of additional working capital, the overall state of the biotechnology industry and other factors set forth in the Company’s filings with the Securities and Exchange Commission. Most of these factors are outside the control of the Company. Investors are cautioned not to put undue reliance on forward-looking statements. Except as otherwise required by applicable securities statutes or regulations, the Company disclaims any intent or obligation to update publicly these forward looking statements, whether as a result of new information, future events or otherwise.
Dr. James Musick
Chief Executive Officer
(303) 999-2130 Ext. 3
Source: Vitro Diagnostics, Inc.